Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research observed that some hypothyroid patients on adequate levothyroxine therapy continue to experience symptoms like poor concentration and hair loss, with findings suggesting an elevated anti-TPO level increases the likelihood of such symptoms, despite normal TSH levels.

This study found that GnRH-A treatment significantly reduced hirsuties scores in women with mild idiopathic hirsuties but did not affect hair growth rate or diameter.

TCHHL1 is a protein important for hair growth, found in hair follicles.

This study found that plantar dermis matrix homogenate can partially restore the regenerative capacity of hair follicles impaired in culture, with CTHRC1 playing a critical role in this process.

In this case report, successful management of a pituitary macroadenoma was achieved with thyroid hormone therapy, leading to reduced tumor size and improvement in symptoms like galactorrhea and headaches.

This study found that transdermal testosterone significantly increased the frequency of satisfactory sexual events in women experiencing SSRI/SNRI-related loss of libido, but did not improve overall sexual self-rating scores.

This study reports a novel TRbeta gene mutation associated with resistance to thyroid hormone syndrome, which may contribute to various forms of alopecia in the affected family members.

This case study details a 57-year-old woman with symptoms of androgen excess, including rapid hair growth and temporal balding, alongside abnormal testosterone levels and a history of chronic renal failure.

In this study, researchers found that Hashimoto's thyroiditis patients, despite being in euthyroid status, experienced more severe extrathyroidal symptoms compared to healthy controls, and elevated thyroid antibodies were linked to lower health-related quality of life and increased inflammation.

This case report illustrates that high-dose biotin supplementation can cause false thyroid function test abnormalities in vitro, emphasizing the need to assess biotin intake before testing.

This historical observation found that parathyroid extract treatment in newborn rats led to a condition resembling scleroderma, characterized by skin hardening, calcium deposition, and possible necrosis.

This study provides a guideline for the safe and effective use of testosterone in women with hypoactive sexual desire disorder, recommending systemic transdermal testosterone for appropriate candidates while highlighting the importance of informed consent and monitoring due to unestablished long-term safety.

This study found that a single injection of Platelet Rich Stroma improved knee function and reduced pain and stiffness in patients with knee osteoarthritis over twelve months.

In this study of a postmenopausal woman with hyperandrogenism, GnRH agonist treatment significantly reduced testosterone levels, suggesting the androgen excess was ovarian in origin and indicating the potential of using GnRH agonists as a conservative treatment option when surgery is not feasible.

This review discusses the diagnosis, management, and hormone treatment of transsexual individuals, and examines the risks and effects of cross-sex hormone therapy without presenting new clinical results.

This narrative review highlights the critical role of intracrine hormone production in peripheral tissues, suggesting that continuous-release subcutaneous testosterone pellet therapy may offer a more effective symptom-driven approach for aging populations, though large-scale randomized controlled trials are needed for confirmation.

In this study, oral Tribulus terrestris extract significantly increased MSH expression in mouse hair follicle melanocytes, suggesting enhanced melanocyte activity and migration.

This study reports an improvement in lymphomatoid papulosis type A in a 52-year-old patient who concurrently used hormone-replacement therapy.

In this study, 35.4% of telogen effluvium patients showed ferritin deficiency and 34.2% had vitamin D deficiency, suggesting these should be included in TE screening; TSH testing should be individualized.

This source describes SH‑1 as a next-generation androgen receptor antagonist designed for localized treatment of androgenetic alopecia, aiming to reverse follicular miniaturization while maintaining endocrine balance. Unlike traditional therapies, SH‑1 offers tissue-specific action, avoiding systemic effects.

This study reports that transdermal exposure to owners' topical hormone replacement therapy caused alopecia in six dogs, but the condition resolved after the therapy was discontinued.

In this case report, researchers observed that a female patient with severe hidradenitis suppurativa experienced complete resolution of her lesions after starting intramuscular exogenous testosterone as part of gender transition, suggesting its potential role in disease remission when other treatments were ineffective.

This review examines the scientific evidence on the short-term safety of testosterone therapy for treating hypoactive sexual desire disorder in women, without presenting new clinical results.

This review discusses cross-sex hormone therapy for managing gender dysphoria in transsexual individuals and reports no new clinical results; it highlights the need for education and culturally sensitive training for healthcare professionals.

This study concludes that hormone therapy can significantly improve skin hydration, elasticity, thickness, and reduce wrinkles by modulating various skin cells through estrogen receptors.

This study concluded that hormonal replacement therapy can improve skin ageing symptoms by increasing skin thickness and alleviating dryness and hyposeborrhoea in postmenopausal women.

This guideline provides recommendations for prescribing systemic testosterone to women with hypoactive sexual desire disorder, emphasizing safe dosing, monitoring, and the need for informed consent despite regulatory challenges.

This review discusses the role of corticotropin-releasing hormone in human skin, focusing on its regulation, receptors, and functions, and highlights parallels with the hypothalamo-pituitary-adrenal axis; it reports no new research findings.

In this case report, a transgender woman experienced scalp hair regrowth after approximately six months of oral estradiol and spironolactone treatment, achieving testosterone levels within the normal female range.

In this study, researchers found that the thyroxine receptor agonist TDM10842 accelerated the onset of anagen, a hair growth phase, in C3H mice, potentially through activation of the Wnt/beta-catenin and Hedgehog pathways, with Pclaf playing a key role in this process.